|
1.
|
Studeny M, Marini FC, Dembinski JL,
Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE and Andreeff
M: Mesenchymal stem cells: potential precursors for tumor stroma
and targeted-delivery vehicles for anticancer agents. J Natl Cancer
Inst. 96:1593–1603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Studeny M, Marini FC, Champlin RE,
Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived
mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
|
|
3.
|
Shen FH, Visger JM, Balian G, Hurwitz SR
and Diduch DR: Systemically administered mesenchymal stromal cells
transduced with insulin-like growth factor-I localize to a fracture
site and potentiate healing. J Orthop Trauma. 16:651–659. 2002.
View Article : Google Scholar
|
|
4.
|
Rochefort GY, Delorme B, Lopez A, Herault
O, Bonnet P, Charbord P, Eder V and Domenech J: Multipotential
mesenchymal stem cells are mobilized into peripheral blood by
hypoxia. Stem Cells. 24:2202–2208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Pittenger MF, Mackay AM, Beck SC, et al:
Multilineage potential of adult human mesenchymal stem cells.
Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Picinich SC, Mishra PJ, Mishra PJ, Glod J
and Banerjee D: The therapeutic potential of mesenchymal stem
cells. Cell- and tissue-based therapy. Expert Opin Biol Ther.
7:965–973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Nakamizo A, Marini F, Amano T, et al:
Human bone marrow-derived mesenchymal stem cells in the treatment
of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI
|
|
8.
|
Mishra PK: Bone marrow-derived mesenchymal
stem cells for treatment of heart failure: is it all paracrine
actions and immunomodulation? J Cardiovasc Med (Hagerstown).
9:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Menon LG, Picinich S, Koneru R, et al:
Differential gene expression associated with migration of
mesenchymal stem cells to conditioned medium from tumor cells or
bone marrow cells. Stem Cells. 25:520–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
McFarlin K, Gao X, Liu YB, et al: Bone
marrow-derived mesenchymal stromal cells accelerate wound healing
in the rat. Wound Repair Regen. 14:471–478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Karnoub AE, Dash AB, Vo AP, et al:
Mesenchymal stem cells within tumour stroma promote breast cancer
metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Mishra PJ, Mishra PJ, Humeniuk R, Medina
DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D:
Carcinoma-associated fibroblast-like differentiation of human
mesenchymal stem cells. Cancer Res. 68:4331–4339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Addadi Y, Moskovits N, Granot D, Lozano G,
Carmi Y, Apte RN, Neeman M and Oren M: p53 status in stromal
fibroblasts modulates tumor growth in an SDF1-dependent manner.
Cancer Res. 70:9650–9658. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kiaris H, Chatzistamou I, Trimis G,
Frangou-Plemmenou M, Pafiti-Kondi A and Kalofoutis A: Evidence for
nonautonomous effect of p53 tumor suppressor in carcinogenesis.
Cancer Res. 65:1627–1630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Houghton J, Li H, Fan X, et al: Mutations
in bone marrow-derived stromal stem cells unmask latent malignancy.
Stem Cells Dev. 19:1153–1166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fukino K, Shen L, Matsumoto S, Morrison
CD, Mutter GL and Eng C: Combined total genome loss of
heterozygosity scan of breast cancer stroma and epithelium reveals
multiplicity of stromal targets. Cancer Res. 64:7231–7236. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Fukino K, Shen L, Patocs A, Mutter GL and
Eng C: Genomic instability within tumor stroma and
clinicopathological characteristics of sporadic primary invasive
breast carcinoma. JAMA. 297:2103–2111. 2007. View Article : Google Scholar
|
|
19.
|
Patocs A, Zhang L, Xu Y, Weber F, Caldes
T, Mutter GL, Platzer P and Eng C: Breast-cancer stromal cells with
TP53 mutations and nodal metastases. N Engl J Med. 357:2543–2551.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kurose K, Gilley K, Matsumoto S, Watson
PH, Zhou XP and Eng C: Frequent somatic mutations in PTEN and TP53
are mutually exclusive in the stroma of breast carcinomas. Nat
Genet. 32:355–357. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Paterson RF, Ulbright TM, MacLennan GT, et
al: Molecular genetic alterations in the
laser-capture-microdissected stroma adjacent to bladder carcinoma.
Cancer. 98:1830–1836. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Dudley AC, Shih SC, Cliffe AR, Hida K and
Klagsbrun M: Attenuated p53 activation in tumour-associated stromal
cells accompanies decreased sensitivity to etoposide and
vincristine. Br J Cancer. 99:118–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Alexandrova A, Ivanov A, Chumakov P,
Kopnin B and Vasiliev J: Changes in p53 expression in mouse
fibroblasts can modify motility and extracellular matrix
organization. Oncogene. 19:5826–5830. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Guo F, Gao Y, Wang L and Zheng Y:
p19Arf-p53 tumor suppressor pathway regulates cell motility by
suppression of phosphoinositide 3-kinase and Rac1 GTPase
activities. J Biol Chem. 278:14414–14419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Molchadsky A, Shats I, Goldfinger N, et
al: p53 plays a role in mesenchymal differentiation programs, in a
cell fate dependent manner. PLoS One. 3:e37072008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hinds P, Finlay C and Levine AJ: Mutation
is required to activate the p53 gene for cooperation with the ras
oncogene and transformation. J Virol. 63:739–746. 1989.PubMed/NCBI
|
|
27.
|
Orimo A, Gupta PB, Sgroi DC, et al:
Stromal fibroblasts present in invasive human breast carcinomas
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12
secretion. Cell. 121:335–348. 2005. View Article : Google Scholar
|
|
28.
|
Kang H, Watkins G, Parr C, Douglas-Jones
A, Mansel RE and Jiang WG: Stromal cell derived factor-1: its
influence on invasiveness and migration of breast cancer cells in
vitro and its association with prognosis and survival in human
breast cancer. Breast Cancer Res. 7:R402–R410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Hasebe T, Tamura N, Okada N, et al: p53
expression in tumor-stromal fibroblasts is closely associated with
the nodal metastasis and outcome of patients with invasive ductal
carcinoma who received neoadjuvant therapy. Hum Pathol. 41:262–270.
2010. View Article : Google Scholar
|
|
30.
|
Trimis G, Chatzistamou I, Politi K, Kiaris
H and Papavassiliou AG: Expression of p21waf1/Cip1 in
stromal fibroblasts of primary breast tumors. Hum Mol Genet.
17:3596–3600. 2008.
|
|
31.
|
Bar J, Feniger-Barish R, Lukashchuk N, et
al: Cancer cells suppress p53 in adjacent fibroblasts. Oncogene.
28:933–936. 2009. View Article : Google Scholar : PubMed/NCBI
|
